199 related articles for article (PubMed ID: 32709911)
1. A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application.
Yeo T; Sealey M; Zhou Y; Saldana L; Loveless S; Claridge TDW; Robertson N; DeLuca G; Palace J; Anthony DC; Probert F
Sci Rep; 2020 Jul; 10(1):12381. PubMed ID: 32709911
[TBL] [Abstract][Full Text] [Related]
2. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
Dickens AM; Larkin JR; Griffin JL; Cavey A; Matthews L; Turner MR; Wilcock GK; Davis BG; Claridge TD; Palace J; Anthony DC; Sibson NR
Neurology; 2014 Oct; 83(17):1492-9. PubMed ID: 25253748
[TBL] [Abstract][Full Text] [Related]
3. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
4. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
5. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
[TBL] [Abstract][Full Text] [Related]
6. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
7. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
[TBL] [Abstract][Full Text] [Related]
8. Analysis of potential microRNA biomarkers for multiple sclerosis.
Al-Temaimi R; Alshammari N; Alroughani R
Exp Mol Pathol; 2024 Jun; 137():104903. PubMed ID: 38772208
[TBL] [Abstract][Full Text] [Related]
9. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
Ibrahim SH; El-Mehdawy KM; Seleem M; El-Sawalhi MM; Shaheen AA
J Neuroimmunol; 2020 Oct; 347():577356. PubMed ID: 32781341
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
Rojas JI; Patrucco L; Alonso R; Garcea O; Deri N; Carnero Contentti E; Lopez PA; Pettinicchi JP; Caride A; Cristiano E
Mult Scler; 2021 Apr; 27(4):579-584. PubMed ID: 32484381
[TBL] [Abstract][Full Text] [Related]
11. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
12. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
13. High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
Hjæresen S; Benedikz E; Sejbaek T; Axelsson M; Novakova L; Zhang M; Lycke J; Illes Z; Fex-Svenningsen Å
J Neurol Sci; 2024 Feb; 457():122888. PubMed ID: 38278096
[TBL] [Abstract][Full Text] [Related]
14. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.
Adalsteinsson E; Langer-Gould A; Homer RJ; Rao A; Sullivan EV; Lima CA; Pfefferbaum A; Atlas SW
AJNR Am J Neuroradiol; 2003; 24(10):1941-5. PubMed ID: 14625214
[TBL] [Abstract][Full Text] [Related]
15. Involvement of cytotoxic Eomes-expressing CD4
Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
[TBL] [Abstract][Full Text] [Related]
16. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
[TBL] [Abstract][Full Text] [Related]
17. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
[No Abstract] [Full Text] [Related]
18. Granzyme B + CD8 + T cells with terminal differentiated effector signature determine multiple sclerosis progression.
Shi Z; Wang X; Wang J; Chen H; Du Q; Lang Y; Kong L; Luo W; Qiu Y; Zhang Y; Li C; Wen D; Yao J; Cheng X; Cai L; Lin X; Wang R; Mou Z; Li S; Liu D; Zhou H; Zhou H; Yang M
J Neuroinflammation; 2023 Jun; 20(1):138. PubMed ID: 37268957
[TBL] [Abstract][Full Text] [Related]
19. Profile of Polish patients with primary progressive multiple sclerosis.
Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
[TBL] [Abstract][Full Text] [Related]
20. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
